Every Form 4 that Entrada Therapeutics, Inc. (TRDA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TRDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRDA filings page.
Entrada Therapeutics, Inc. (TRDA) had common stock sales reported by investment funds affiliated with MPM BioVentures, which are ten percent owners. On September 4, 2026, affiliated funds sold 38,500 shares at a weighted average price of $7.11 per share, with individual sale prices ranging from $7.01 to $7.16. On September 8, 2026, they sold 192,500 shares at a weighted average price of $7.41 per share, with sale prices between $6.97 and $7.70. On September 9, 2026, they sold an additional 28,837 shares at a weighted average price of $7.13, with sale prices between $7.02 and $7.54. After the last reported sale, the funds continued to hold large positions, including 1,764,167 shares held by MPM BioVentures 2014, L.P. and 1,810,592 shares held by MPM BioVentures 2018, L.P. The reporting persons state that each of them disclaims beneficial ownership of the securities except to the extent of their respective pecuniary interest and no Rule 10b5-1 trading plan is reported.
Entrada Therapeutics, Inc. (TRDA) reported that investment funds affiliated with MPM BioVentures, which are ten percent owners, made indirect open-market sales of an aggregate 259,837 shares of Common Stock over three days in September 2026. The sales were executed at weighted average prices between roughly $7.01 and $7.70 per share, with the shares held across multiple MPM partnerships and LLCs. Each reporting person disclaims beneficial ownership beyond its pecuniary interest, and no Rule 10b5-1 trading plan is reported.
Entrada Therapeutics, Inc. (TRDA) reported that investment entities affiliated with MPM BioVentures, including MPM BioVentures 2018, L.P. and related funds, sold a total of 86,482 shares of Common Stock in open-market transactions on September 1–3, 2026. Daily sales were 29,088 shares at a weighted average price of about $7.06 on September 1, 25,131 shares at about $7.19 on September 2, and 32,263 shares at about $7.17 on September 3, each within the price ranges disclosed in the notes. The shares are held across multiple MPM limited partnerships and LLCs, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
Entrada Therapeutics, Inc. (TRDA) had affiliated investment funds jointly report open-market or private sales of a total of 86,482 shares of common stock on September 1–3, 2026, at weighted average prices of about $7.06, $7.19 and $7.17 per share, all held indirectly through MPM BioVentures entities, which each reporting person disclaims beneficial ownership of except for its pecuniary interest.
Entrada Therapeutics, Inc. (TRDA) director and CEO Dipal Doshi reported a Form 4 transaction involving 8,724 shares of common stock on September 2, 2026. The shares were disposed of at a weighted average price of $7.1439 under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations and did not represent a discretionary trade. After this tax-withholding disposition, Doshi directly holds 517,290 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. (TRDA) reported that its President & COO, Nathan J. Dowden, had 2,528 shares of common stock disposed of on September 2, 2026 to satisfy minimum statutory tax withholding obligations. The shares were automatically sold by the company under a mandatory sell-to-cover provision and were not a discretionary trade. After this withholding-related sale, Dowden directly holds 196,060 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. (TRDA) reported that Sethuraman Natarajan, its President, Research & Develop., had 2,079 shares of common stock disposed of on September 2, 2026 to satisfy minimum statutory tax withholding obligations. The shares were automatically sold by the company under a mandatory sell-to-cover provision and were not a discretionary trade by the insider. Following this tax-withholding transaction, Natarajan directly holds 214,238 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. (TRDA) reported that its Chief Financial Officer, Kory James Wentworth, had 1,733 shares of common stock disposed of on September 2, 2026 to satisfy minimum statutory tax withholding obligations. The shares were automatically sold by the company under a mandatory sell-to-cover provision and were not a discretionary trade. After this tax-withholding transaction, the CFO directly held 117,277 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. (TRDA) reported that investment entities affiliated with MPM BioVentures, including MPM BioVentures 2018, L.P., MPM BioVentures 2018 LLC and MPM BioVentures 2018 GP LLC as ten percent owners, conducted open‑market sales of Entrada common stock. Over August 27–31, 2026, these affiliated funds sold an aggregate 86,914 shares indirectly held, in three transactions of 38,922; 3,733; and 44,259 shares, at weighted average prices around $7 per share within disclosed price ranges. The shares are held across several MPM BioVentures funds, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest. The Rule 10b5‑1 trading plan checkbox was not marked as applicable.
Entrada Therapeutics, Inc. (TRDA) had indirect shareholders affiliated with the MPM BioVentures funds report open-market sales of its common stock. Across three transactions on August 27, 28 and 31, 2026, entities including MPM BioVentures 2014, L.P., MPM BioVentures 2018, L.P. and related funds sold a total of 86,914 shares at weighted average prices ranging from about $6.76 to $7.37 per share. After the August 31 transaction, shares were held among these entities as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest.
Entrada Therapeutics, Inc. (TRDA) reported that investment funds affiliated with MPM BioVentures, as ten percent owners, sold a total of 62,714 shares of Common Stock in open‑market or private transactions on August 24–26, 2026 at weighted‑average prices described in price ranges between approximately $6.97 and $7.64 per share.
The sales were executed indirectly through multiple MPM BioVentures partnerships and LLCs, and each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest. After the August 26, 2026 transactions, MPM BioVentures entities collectively continued to hold substantial TRDA positions as detailed in the footnotes.
Entrada Therapeutics, Inc. (TRDA) had affiliated investment entities associated with MPM BioVentures, including MPM BioVentures 2018, L.P., a ten percent owner, report open-market sales of an aggregate 62,714 shares of common stock over three days at weighted average prices around the reported per-share figures. The sales were made indirectly through several MPM BioVentures and related LLC and limited partnership vehicles, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest.
Entrada Therapeutics director Kush Parmar reported indirect sales of 155,255 shares of Common Stock of Entrada Therapeutics, Inc., executed by investment entities he helps manage. The shares were sold on August 6, 7, and 10, 2026 at weighted average prices in the $6.80–$7.20 per-share range. After these transactions, an affiliated fund, 5AM Opportunities I, L.P., is reported as indirectly holding 1,093,313 shares, with Parmar disclaiming beneficial ownership beyond his pecuniary interest.
Entrada Therapeutics, Inc. reported that investment funds affiliated with 5AM Ventures, a 10% stockholder, sold a total of 62,811 shares of Common Stock in open-market transactions on August 6–7, 2026, at weighted average prices of $7.00 and $6.85 per share. The August 6 sale of 10,494 shares occurred within a price range of $6.90–$7.11, and the August 7 sale of 52,317 shares occurred within a price range of $6.80–$7.01. Following these transactions, an affiliated fund, 5AM Opportunities I, L.P., is reported as holding 1,093,313 shares of Entrada Therapeutics Common Stock indirectly. Certain managing members of the general partners may be deemed to share voting and investment power over these fund-held shares, while disclaiming beneficial ownership except to the extent of their pecuniary interest.
5AM Ventures V, L.P., a ten percent shareholder of Entrada Therapeutics, reported open-market or private sales totaling 116,474 shares of common stock on July 30–31, 2026, at prices including a weighted average of $6.93 per share (with trades from $6.75 to $6.95) and $6.85 per share. Separately, 1,093,313 shares are reported as indirectly held as of July 30, 2026 by 5AM Opportunities I, L.P., with affiliated entities and individuals disclaiming beneficial ownership except to the extent of their pecuniary interests.
Entrada Therapeutics director and 10% owner Kush M. Parmar, through entities affiliated with 5AM Ventures, reported open-market sales totaling 116,474 shares of common stock on July 30–31, 2026 at per-share prices around 6.9300 and 6.8500. Shares are held by 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., with Parmar disclaiming beneficial ownership beyond his pecuniary interest.
Entrada Therapeutics director and 10% owner Kush Parmar received a grant of stock options covering 19,000 shares of Common Stock. The options have an exercise price of $5.97 per share and expire on June 10, 2036. These options vest on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders.
Entrada Therapeutics director Peter S. Kim received a grant of stock options covering 19,000 shares of common stock. The options have an exercise price of $5.97 per share and expire on June 10, 2036. According to the terms, they vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders.
Entrada Therapeutics director Gina Chapman received a grant of stock options to buy 19,000 shares of common stock at an exercise price of $5.97 per share. These options vest on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders and expire on June 10, 2036.
Entrada Therapeutics director Radhakrishnan Maha received a grant of 19,000 stock options. Each option allows the purchase of one share of common stock at an exercise price of $5.97 per share and was granted at no cost.
The options vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or Entrada’s next annual meeting of stockholders, and expire on June 10, 2036. After this grant, Maha holds 19,000 stock options directly.
Entrada Therapeutics director Mary Thistle received a stock option grant covering 19,000 shares of common stock. The option has an exercise price of $5.97 per share and expires on June 10, 2036. According to the terms, the award vests on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders. This is a compensation-related grant rather than an open-market trade.
Entrada Therapeutics director Bernhardt G. Zeiher received a grant of stock options covering 19,000 shares of common stock. The options have an exercise price of $5.97 per share and expire on June 10, 2036. They vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders.
Entrada Therapeutics director-related trust buys shares. A revocable living trust associated with director Bernhardt G. Zeiher purchased 5,000 shares of Entrada Therapeutics common stock in an open-market transaction at a weighted average price of $5.8632 per share, with trade prices ranging from $5.86 to $6.00. Following the purchase, the trust holds 5,000 shares indirectly, and Dr. Zeiher disclaims beneficial ownership beyond any pecuniary interest.
Entrada Therapeutics, Inc. executive Sethuraman Natarajan, President of Research & Development, reported an open-market sale of 25,907 shares of Common Stock at a weighted average price of $15.3939 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024, and Natarajan now directly holds 216,317 shares.
Entrada Therapeutics President & COO Nathan J. Dowden reported an option exercise and related share sale. He exercised stock options to acquire 15,000 shares of common stock at $1.74 per share, then sold 15,000 shares of common stock in an open-market transaction at a weighted average price of $15.3302 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. Following the sale, Dowden directly owns 198,588 shares of common stock and holds 49,831 stock options exercisable for common stock as of the reported date.
Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 2,500 shares of Common Stock in an open-market transaction. The sale occurred at a price of $12.95 per share. After the trade, he directly holds 119,010 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 6, 2025, indicating it was pre-scheduled.
Entrada Therapeutics President & COO Nathan J. Dowden reported open-market sales of a total of 15,010 shares of common stock. He sold 3,116 shares on March 9, 2026 at a weighted average price of $13.024 per share and 11,894 shares on March 10, 2026 at a weighted average price of $13.0476 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the most recent sale, Dowden directly holds 198,588 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. Chief Financial Officer Kory James Wentworth reported open-market sales of company common stock. He sold 5,089 shares on March 9, 2026 at a weighted average price of $13.0011 per share and 11,388 shares on March 10, 2026 at a weighted average price of $13.0151 per share. These transactions, totaling 16,477 shares, were executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2025. After the most recent sale, he directly holds 121,510 shares of Entrada common stock.
Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 7,988 shares of common stock in an open-market transaction. The sale occurred on March 4, 2026 at a weighted average price of $12.2549 per share, with individual trade prices ranging from $11.80 to $12.57.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on March 6, 2025. Following this sale, Wentworth directly holds 137,987 shares of Entrada Therapeutics common stock.
Entrada Therapeutics CEO Dipal Doshi reported new equity awards and automatic tax-related share sales. On March 1, 2026, Doshi received 139,400 restricted stock units under the 2021 Stock Option and Incentive Plan and a stock option covering 208,000 shares of common stock, both granted at $0.00 per share.
The RSUs vest in four 25% installments each March 1 from 2027 through 2030, while 25% of the option vests on March 1, 2027 and the rest monthly through March 1, 2030. On March 2 and 3, 2026, a total of 29,050 shares of common stock were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding, at weighted average prices of $11.6579 and $11.7564 per share.
Following these transactions, Doshi directly owned 526,014 shares of Entrada Therapeutics common stock.
Entrada Therapeutics Chief Financial Officer Kory James Wentworth reported equity compensation grants and related tax-withholding share dispositions. On March 1, 2026, he received 66,600 stock options and 44,600 restricted stock units under the 2021 Stock Option and Incentive Plan, both vesting in stages through March 1, 2030.
The filing also shows mandatory sell-to-cover transactions where the company automatically sold 5,712 shares at a weighted average price of $11.7564 on March 3, 2026 and 2,939 shares at $11.6579 on March 2, 2026 to cover minimum statutory tax withholding obligations, not discretionary trades by Wentworth. After these transactions, he directly owned 145,975 common shares and 66,600 options.
Entrada Therapeutics President & COO Nathan J. Dowden reported equity compensation grants and related tax-withholding share dispositions. On March 1, 2026, he received 55,800 shares of common stock as restricted stock units and a stock option for 83,200 shares, both granted at $0.00 per share.
The RSUs vest in four equal 25% installments each March 1 from 2027 through 2030, while the option vests 25% on March 1, 2027 and the remaining 75% in 36 monthly installments through March 1, 2030. On March 2 and March 3, 2026, a total of 21,261 shares of common stock were automatically disposed of at weighted average prices of $11.6579 and $11.7564 to satisfy minimum statutory tax withholding obligations under a mandatory sell-to-cover provision, and did not represent discretionary trades. After these transactions, Dowden directly held 213,598 shares of common stock and 83,200 option shares.
Entrada Therapeutics, Inc. reported that President of Research & Development Sethuraman Natarajan received new equity awards and had shares disposed to cover tax obligations. On March 1, 2026, he was granted 55,800 restricted stock units (RSUs), each representing one share of common stock, scheduled to vest 25% each on March 1, 2027, March 1, 2028, March 1, 2029, and March 1, 2030, contingent on continued service. He also received a stock option for 83,200 shares of common stock, with 25% vesting on March 1, 2027 and the remaining 75% vesting in 36 equal monthly installments through March 1, 2030. To satisfy minimum statutory tax withholding obligations, the company automatically sold shares on his behalf: 3,898 shares of common stock on March 2, 2026 at a weighted average price of $11.6579 (across trades from $11.17 to $11.91) and 7,577 shares on March 3, 2026 at a weighted average price of $11.7564 (across trades from $11.22 to $12.095). After these transactions, he directly owned 242,224 shares of Entrada’s common stock.
Entrada Therapeutics, Inc. (TRDA) reported an insider stock sale by its Chief Financial Officer. On 11/21/2025, the CFO sold 8,910 shares of common stock in an open-market transaction at a weighted average price of $9.9811 per share. The shares were sold in multiple trades at prices ranging from $9.95 to $10.05.
The transaction was executed pursuant to a Rule 10b5-1 trading plan that the reporting person adopted on March 6, 2025. Following this sale, the CFO beneficially owns 110,026 shares of Entrada Therapeutics common stock in direct ownership.
Entrada Therapeutics, Inc. (TRDA) reported open-market purchases of its common stock by Baker Brothers–affiliated investment funds and related reporting persons. On November 20, 2025, the funds bought multiple blocks of Entrada common stock, including 1,213 and 1,186 shares at weighted-average prices of $9.0688 and $9.0728, respectively. Additional blocks of 13,386 and 13,082 shares were also acquired at the same respective weighted-average prices.
After these trades, one indirect holding reported in Table I rose to 380,152 shares of common stock and a second to 381,338 shares, with larger indirect positions of 4,678,310 and 4,691,392 shares reported for other related entities. The filing explains that Baker Brothers’ principals and advisory entities may be deemed to have indirect pecuniary interests through their limited partnership and advisory relationships, while expressly disclaiming beneficial ownership beyond their economic interests.
Entrada Therapeutics (TRDA) reported an insider share sale by a major holder. On 11/14/2025, an entity affiliated with director and 10% owner Kush M. Parmar, M.D., Ph.D., sold 200,000 shares of Entrada Therapeutics common stock in an open-market transaction at a weighted average price of $8.80 per share, with individual sale prices ranging from $8.80 to $9.023.
Following this transaction, 5AM Ventures V, L.P. is shown as beneficially owning 2,963,066 shares indirectly, and 5AM Opportunities I, L.P. is shown as beneficially owning 1,093,313 shares indirectly. Dr. Parmar may be deemed to share voting and investment power over these positions through general partner entities, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
Entrada Therapeutics, Inc. (TRDA) reported an insider transaction by funds affiliated with 5AM Venture Management. On 11/14/2025, the reporting persons sold 200,000 shares of Entrada common stock at a weighted average price of $8.80 per share, with individual trades executed between $8.80 and $9.023. After this sale, one fund held 2,963,066 shares directly, and another affiliated fund held 1,093,313 shares indirectly. The filing notes that managing members of the general partners may be deemed to share voting and investment power over these holdings and that some of them disclaim beneficial ownership beyond their economic interest.